Hua Medicine of Shanghai announced positive results from a China Phase Ib trial of HMS5552 (sinogliatin) in patients with diabetes. The molecule is a novel oral 4th-generation glucokinase activator (GKA) for Type 2 diabetes that Hua in-licensed from Roche in 2011. In the trial, sinogliatin provided patients with 24-hour glucose control of both fasting plasma glucose and post-meal glucose levels, something that usually requires two separate drugs. Hua expects to start a China Phase II trial and to complete a US Phase I trial of sinogliatin before the end of 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
